MCS researcher Martin Pall to speak in five European countries

[Guest guest]

MCS researcher Martin Pall to speak in five European countries

_http://www.thecanaryreport.org/2010/02/01/mcs-researcher-martin-pall/?utm_s

ource=feedburner & utm_medium=email & utm_campaign=Feed%3A+TheCanaryReport+%28Th

e+Canary+Report%29_

(http://www.thecanaryreport.org/2010/02/01/mcs-researcher-martin-pall/?utm_sourc\

e=feedburner & utm_medium=email & utm_campaign=Feed:+The

CanaryReport+(The+Canary+Report))

 

 

Martin Pall announces speaking tour in five European countries starting

April 10.

 

Guest post by _Martin L. Pall_ (http://thetenthparadigm.org/index.html) ,

Professor Emeritus of Biochemistry and Basic Medical Sciences, Washington

State University and Research Director, the Tenth Paradigm Research Group.

 

 

I will be giving 11 talks in five countries in Europe, starting on the

tenth of April, all on _the NO/ONOO cycle_

(http://thetenthparadigm.org/index.html) . Nine of these are being scheduled to

correspond with my trip to

Europe, including several entire meetings. The talks are as follows:

 

 

I will start with an all day workshop in Berlin, to be presented by me and

also Dr. Peter Ohnsorge. My presentation will be simultaneously translated

into German. I will speak on multiple chemical sensitivity (MCS) and on

therapy and may discuss other topics that will be covered in my talk in

London which follows.

 

 

In London, I will be presenting three 90 minute talks, for a total of 4

1/2 hours, all at the Royal Society of Medicine, one of the most prestigious

locations in the world. The first talk will focus on the NO/ONOO-cycle

mechanism and how it plays out in the etiology of CFS/ME and also fibromyalgia.

The second talk will focus on how that same mechanism explains MCS and

also the three classic neurodegenerative diseases: Alzheimer’s, Parkinson’s

and ALS. The three neurodegenerative diseases were also discussed as

apparent NO/ONOO-cycle diseases in my book, “Explaining ‘Unexplained

Illnesses’â€

, but there is substantial new evidence that further buttresses the case.

Specifically, there is compelling evidence, that the four specific features,

the formation of amyloid beta protein (A-beta) aggregates in Alzheimer’s,

the formation of hyperphosphorylated tau protein aggregates leading to

neurofibrillary tangles (also Alzheimer’s), the formation of Lewy bodies

(Parkinson’s) and the formation of neurofilament aggregates (ALS) are all

formed

under the influence of NO/ONOO-cycle elements of which peroxynitrite is the

most important but several others have roles as well. What is interesting

is that both A-beta aggregates and neurofilament aggregates act, in turn, to

increased NO/ONOO-cycle elements, acting therefore as tissue-specific

elements of the cycle. Recent studies of the A-beta aggregates have elucidated

the mechanism by which this occurs.

 

 

The third talk at the Royal Society of Medicine will be entirely on therapy

– how we can be down-regulate the NO/ONOO cycle.

 

 

I then fly on to Rome for a presentation on the morning of April 17,

flying later that day to Catania, Sicily for a meeting on MCS. That meeting is

again being scheduled to correspond to my European trip and is the first

meeting ever to be held in Italy on MCS. I then return to Rome for an informal

meeting with people at the National Institute of Health to discuss the

mechanism of MCS. The situation in Italy is an amazing turn around compared

with the situation when I visited there in November 2008. At that time, and I

gave talks at the medical school in Brescia in Northern Italy and also in

Rome, I was told that the situation regarding MCS in Italy was positively

barbaric, with physicians being prosecuted and thrown in jail for treating

their patients for MCS. Maybe, just maybe, I will have turned the situation

around in that country within 1 1/2 years? We can only hope.

 

 

From Rome, I fly to Paris to talk at a meeting on MCS. That meeting is the

first meeting ever to be held on MCS in France and was again scheduled to

correspond to my European trip. It follows a talk that I gave at the

Environmental Medicine meeting in Aix-en-Provence last April. The latter talk

was

the first talk ever given on MCS at the French Environmental Medicine

meeting, a meeting that in the past, was largely dominated by environmental

carcinogenesis. The situation in France has change dramatically in other ways.

My web page paper on MCS has been translated into German and French and

the response in both countries have been impressive. The French professional

society of allergists has asked for and been given permission to post that

French translation on their web site. Both French and German translations

have been placed on several web sites.

 

 

After the Paris meeting, I go to Wurzburg for another meeting– an already

scheduled one. I have been asked explicitly to give two talks– one on

Alzheimer’s, Parkinson’s and ALS as NO/ONOO-cycle diseases– this will

follow

much of the material I outlined above on this topic for the London meeting. I

have also been asked to give a talk on therapy– how we can down-regulate

the NO/ONOO cycle.

 

 

After the Wurzburg meeting, it’s on to Madrid for the last meeting of the

trip. I am not completely sure what I will be speaking on at that meeting,

but am leaning towards talking about excessive NMDA activity as a common “

end point†of large numbers of environmental toxicants. This is, in some

ways, the most important new understanding that came out of my recently

published big MCS review– that large numbers of environmental toxicants all

produce increases in NMDA activity and have been shown to have their toxic

responses greatly lowered by NMDA antagonists. Previously, there have been two

major toxicant end points– what has been called genotoxicity for many

carcinogens– and a second, endocrine disruption. So this is a third, and it

is

almost certainly more important than endocrine disruption in terms of its

implications for human health.

 

 

I had a wonderful trip to Europe in November 2008, ending up that

six-country speaking tour as the only non-European invited to a special session

of

the Council of Nations (the EU Parliament) on environmental medicine, but

this next one promises to be even better.

 

 

Martin L. (Marty) Pall

Professor Emeritus of Biochemistry and Basic Medical Science at Washington

State University

503-232-3883

_martin_pall_ (martin_pall)

_thetenthparadigm.org_ (http://thetenthparadigm.org/index.html)